Anti-Mullerian Hormone as Predictor of Ovarian Responce to Clomiphene Citrate in PCOS

Study Overview
=================
Brief Summary
-----------------
Polycystic ovary syndrome (PCOS) is found in 5% to 6% of women of reproductive age. It affects women's reproductive capability; thus patients have risks of infertility, miscarriage, and complicated pregnancy. A study revealed that the prevalence of oligoovulation or anovulation in patients with PCOS ranged from 65% to 80%. Anti-Mullerian Hormone (AMH) is an important regulator in the ovary that play a rule during development and function. It is suspected to affect clomiphene citrate (cc) resistance. In this study the investigator will assess the accuracy of AMH prediction of response to cc in women with PCOS.

Official Title
-----------------
Circulating Anti-mullerian Hormone as Predictor of Ovarian Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome

Conditions
-----------------
Polycystic Ovary Syndrome

Intervention / Treatment
-----------------
* Drug: Clomiphene Citrate
* Diagnostic Test: Follicular growth


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women diagnosed with PCOS Women 20-35 years old. BMI ≤30 kg/m without previous ovulation induction. Partners with normal semen parameters Parameter World Health Organization (WHO) 2010 Volume1.5 ml Concentration 15 million/ml Progressive motility 32% Normal forms 4% Exclusion Criteria: Women with evidence of hyper-or hypothyroidism, hyperprolactinemia, Cushing's syndrome, congenital adrenal hyperplasia or androgen-secreting tumors. Women with factors of infertility other than PCOS Women with incomplete data.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group A: CC & ovulation<br>AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels. | Drug: Clomiphene Citrate<br>* 100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods<br>* Other names: Clomide;Diagnostic Test: Follicular growth<br>* Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.<br>|
| Experimental: Group B: CC & no ovulation<br>AMH level is measured before Clomiphene citrate 100 mg daily for 5 days & detecting Follicular growth assessment by TVU will be performed at day 12 of the menstrual period. Successful and unsuccessful follicular growth will be compared according to the subjects' respective AMH levels. | Drug: Clomiphene Citrate<br>* 100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods<br>* Other names: Clomide;Diagnostic Test: Follicular growth<br>* Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AMH in prediction of Ovulation in women with PCOS. | AMH level is measured 10 days before expected date of ovulation then correlated to ovulation either successfully or not. | 10 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anti-mullerian hormone